Recent Data on Axi-Cel in Lymphoma

EP: 1.The Evolving Treatment Landscape of Leukemia

EP: 2.Recent Data from ASH 2023 in Leukemia

EP: 3.Long-Term Results of the OPTIC Trial in CML

EP: 4.Subgroup Analysis of the Phase 3 PhALLCON Study of Ponatinib in Ph+ ALL

EP: 5.Key Takeaways from Recent Updates in Leukemia

EP: 6.Challenges in Managing Adverse Events and Unmet Needs in Leukemia

EP: 7.The Evolving Lymphoma Treatment Landscape

EP: 8.Subcutaneous Mosunetuzumab in Follicular Lymphoma

Now Viewing

EP: 9.Recent Data on Axi-Cel in Lymphoma

EP: 10.Primary Analysis of the SYMPATICO trial in Mantle Cell Lymphoma

EP: 11.CAR T-Cell Therapy: Managing Adverse Events and Assessing Patient Response in Lymphoma

EP: 12.Unmet Needs and Challenges in Lymphoma

This is a synopsis of a Peer Exchange series featuring James K. McCloskey, MD, and Lori A. Leslie, MD, of John Theurer Cancer Center, Hackensack University Medical Center.

Dr. Lori Leslie, Associate Professor of Medicine and Director of Indolent Lymphoma and CLL Research Programs at the John Theurer Cancer Center, discusses a subgroup analysis from the ZUMA-7 trial presented at the 2022 ASH Annual Meeting. ZUMA-7 previously demonstrated superior event-free survival, progression-free survival, and overall survival with axicabtagene ciloleucel (axi-cel) CAR T-cell therapy versus standard salvage chemotherapy/autologous stem cell transplant for relapsed/refractory diffuse large B-cell lymphoma patients within 12 months of frontline treatment.

This new analysis specifically evaluated patients over 65 years old, comprising around 70 patients including some over 70. It revealed consistent overall survival benefits from axi-cel in this older population, with hazard ratios of 0.69 for those 65-70 years old and an even more impressive 0.33 for those over 70 years old. Thus, advanced age alone should not preclude CAR T-cell therapy consideration if patients otherwise meet eligibility criteria. Dr. Leslie explains extensive real-world experience demonstrates feasibility and efficacy of CAR T-cell therapy for lymphoma patients even over 80 years old, with manageable toxicity. While the ZUMA-7 population was younger and fitter than typical real-world patients, this study clearly demonstrates elderly patients derive significant overall survival gains from axi-cel versus standard therapies.

Given older patients are often offered fewer options, this provides vital evidence to support aggressively advocating CAR T-cell therapy for eligible relapsed/refractory diffuse large B-cell lymphoma patients regardless of age. Dr. Leslie suggests this data should prompt strong consideration of axi-cel as early as second-line for older DLBCL patients given its survival benefits over even autologous stem cell transplant.

*Video synopsis is AI-generated and reviewed by OncLive editorial staff.